Log In
Print
BCIQ
Print
Print this Print this
 

TRV130

  Manage Alerts
Collapse Summary General Information
Company Trevena Inc.
DescriptionG protein-biased mu opioid receptor (MOR; OPRM1) ligand
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain; Treat moderate to severe acute postoperative pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today